NO20051965L - Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander. - Google Patents

Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.

Info

Publication number: NO20051965L
Authority: NO; Norway
Prior art keywords: chemokine; treatment; mediated disease; disease states; piperidine derivatives
Prior art date: 2002-09-24

Application number

NO20051965A

Other languages

English (en)

Norwegian (no)

Other versions

NO20051965D0 (no

Inventor

Brian Springthorpe

Matthew Perry

Christopher Luckhurst

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-24

Filing date

2005-04-22

Publication date

2005-06-23

2005-04-22 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-04-22 Publication of NO20051965D0 publication Critical patent/NO20051965D0/no

2005-06-23 Publication of NO20051965L publication Critical patent/NO20051965L/no

Links

102000019034 Chemokines Human genes 0.000 title abstract 2
108010012236 Chemokines Proteins 0.000 title abstract 2
201000010099 disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
230000001404 mediated effect Effects 0.000 title abstract 2
150000003053 piperidines Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
102100024167 C-C chemokine receptor type 3 Human genes 0.000 abstract 1
101710149862 C-C chemokine receptor type 3 Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Virology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)

NO20051965A 2002-09-24 2005-04-22 Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander. NO20051965L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0202838A SE0202838D0 (sv)	2002-09-24	2002-09-24	Chemical compounds
PCT/SE2003/001425 WO2004029041A1 (en)	2002-09-24	2003-09-12	Novel piperidine derivatives for use in the treatment of chemokine mediated disease states

Publications (2)

Publication Number	Publication Date
NO20051965D0 NO20051965D0 (no)	2005-04-22
NO20051965L true NO20051965L (no)	2005-06-23

Family

ID=20289093

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20051965A NO20051965L (no)	2002-09-24	2005-04-22	Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.

Country Status (20)

Country	Link
US (1)	US20060040984A1 (de)
EP (2)	EP1546130B1 (de)
JP (1)	JP2006503066A (de)
KR (1)	KR20050052511A (de)
CN (1)	CN1684952A (de)
AT (1)	ATE368656T1 (de)
AU (1)	AU2003259004B2 (de)
BR (1)	BR0314688A (de)
CA (1)	CA2497280A1 (de)
DE (1)	DE60315323T2 (de)
ES (1)	ES2289354T3 (de)
IS (1)	IS7813A (de)
MX (1)	MXPA05003007A (de)
NO (1)	NO20051965L (de)
NZ (1)	NZ538527A (de)
PL (1)	PL376119A1 (de)
RU (1)	RU2005105053A (de)
SE (1)	SE0202838D0 (de)
WO (1)	WO2004029041A1 (de)
ZA (1)	ZA200502341B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR033517A1 (es) *	2000-04-08	2003-12-26	Astrazeneca Ab	Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
ATE319703T1 (de)	2001-07-02	2006-03-15		Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
GB0120461D0 (en)	2001-08-22	2001-10-17	Astrazeneca Ab	Novel compounds
GB0122503D0 (en)	2001-09-18	2001-11-07	Astrazeneca Ab	Chemical compounds
AU2003209204A1 (en) *	2002-01-10	2003-07-30	University Of Washington	Hydrogels formed by non-covalent linkages
SE0200843D0 (sv) *	2002-03-19	2002-03-19	Astrazeneca Ab	Chemical compounds
SE0200844D0 (sv) *	2002-03-19	2002-03-19	Astrazeneca Ab	Chemical compounds
SE0300957D0 (sv) *	2003-04-01	2003-04-01	Astrazeneca Ab	Chemical compounds
SE0301368D0 (sv) *	2003-05-09	2003-05-09	Astrazeneca Ab	Chemical compounds
SE0400925D0 (sv) *	2004-04-06	2004-04-06	Astrazeneca Ab	Chemical compounds
GB0417804D0 (en) *	2004-08-10	2004-09-15	Novartis Ag	Organic compounds
KR100896546B1 (ko)	2004-08-10	2009-05-07	노파르티스 아게	Ｃｃｒ３ 억제 활성을 갖는 피페라진 유도체
EP1888527A1 (de) *	2005-05-27	2008-02-20	AstraZeneca AB	Piperidine zur behandlung von chemokinvermittelten krankheiten
TW200722419A (en) *	2005-05-27	2007-06-16	Astrazeneca Ab	Chemical compounds
JP2009501793A (ja)	2005-07-21	2009-01-22	アストラゼネカ・アクチエボラーグ	新規ピペリジン誘導体
CA2625762A1 (en)	2005-10-11	2007-04-26	Schering Corporation	Substituted heterocyclic compounds with cxcr3 antagonist activity
TWI433838B (zh) *	2008-06-25	2014-04-11	必治妥美雅史谷比公司	作為趨化因子受體活性調節劑之六氫吡啶衍生物
GB0908394D0 (en)	2009-05-15	2009-06-24	Univ Leuven Kath	Novel viral replication inhibitors
GB0913636D0 (en) *	2009-08-05	2009-09-16	Univ Leuven Kath	Novel viral replication inhibitors
KR20140003438A (ko)	2010-11-15	2014-01-09	카톨리에케 유니버시테이트 루벤	항바이러스성 축합 헤테로사이클릭 화합물
BR112014015197A8 (pt)	2011-12-21	2017-06-13	Novira Therapeutics Inc	agentes antivirais de hepatite b
KR102271574B1 (ko)	2012-08-28	2021-07-01	얀센 사이언시즈 아일랜드 언리미티드 컴퍼니	설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
WO2014131847A1 (en)	2013-02-28	2014-09-04	Janssen R&D Ireland	Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
MX353412B (es)	2013-04-03	2018-01-10	Janssen Sciences Ireland Uc	Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
TWI733288B (zh)	2013-05-17	2021-07-11	愛爾蘭商健生科學愛爾蘭無限公司	胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
DK2997019T3 (en)	2013-05-17	2018-12-03	Janssen Sciences Ireland Uc	SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
HRP20180791T1 (hr)	2013-07-25	2018-09-07	Janssen Sciences Ireland Uc	Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
CA2923712C (en)	2013-10-23	2021-11-02	Janssen Sciences Ireland Uc	Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10392349B2 (en)	2014-01-16	2019-08-27	Novira Therapeutics, Inc.	Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en)	2014-01-16	2015-10-27	Novira Therapeutics, Inc.	Azepane derivatives and methods of treating hepatitis B infections
CA2936947A1 (en)	2014-02-05	2015-08-13	Novira Therapeutics, Inc.	Combination therapy for treatment of hbv infections
TW201620893A (zh)	2014-02-06	2016-06-16	健生科學愛爾蘭無限公司	磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途
JP2018510159A (ja)	2015-03-19	2018-04-12	ノヴィラ・セラピューティクス・インコーポレイテッド	アゾカン及びアゾナン誘導体及びｂ型肝炎感染症の治療法
US10875876B2 (en)	2015-07-02	2020-12-29	Janssen Sciences Ireland Uc	Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
TW201718496A (zh)	2015-09-29	2017-06-01	諾維拉治療公司	B型肝炎抗病毒劑之晶型
AU2017248828A1 (en)	2016-04-15	2018-11-01	Janssen Sciences Ireland Uc	Combinations and methods comprising a capsid assembly inhibitor
MX2020009531A (es)	2018-03-14	2020-10-05	Janssen Sciences Ireland Unlimited Co	Regimen posologico del modulador del ensamblaje de la capside.
WO2020169784A1 (en)	2019-02-22	2020-08-27	Janssen Sciences Ireland Unlimited Company	Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
AR119732A1 (es)	2019-05-06	2022-01-05	Janssen Sciences Ireland Unlimited Co	Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4505915A (en) *	1979-05-29	1985-03-19	Merck & Co., Inc.	6-N-Heterocyclyl penicillins
US4588722A (en) *	1984-01-09	1986-05-13	Janssen Pharmaceutica N.V.	N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
US4695575A (en) *	1984-11-13	1987-09-22	Janssen Pharmaceutica, N.V.	4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
US5889006A (en) *	1995-02-23	1999-03-30	Schering Corporation	Muscarinic antagonists
IL117149A0 (en) *	1995-02-23	1996-06-18	Schering Corp	Muscarinic antagonists
US5952349A (en) *	1996-07-10	1999-09-14	Schering Corporation	Muscarinic antagonists for treating memory loss
ES2182104T3 (es) *	1996-07-10	2003-03-01	Schering Corp	Piperidinas 1,4-disustituidas como antagonistas muscarinicos.
JP3390179B2 (ja) *	1996-08-15	2003-03-24	シェーリングコーポレイション	エーテルムスカリン様アンタゴニスト
US5977138A (en) *	1996-08-15	1999-11-02	Schering Corporation	Ether muscarinic antagonists
TWI245763B (en) *	1998-04-02	2005-12-21	Janssen Pharmaceutica Nv	Biocidal benzylbiphenyl derivatives
WO1999055674A1 (en) *	1998-04-28	1999-11-04	Dainippon Pharmaceutical Co., Ltd.	1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
US6066636A (en) *	1998-06-30	2000-05-23	Schering Corporation	Muscarinic antagonists
EP1091956B1 (de) *	1998-06-30	2004-08-04	Schering Corporation	Muskarin-rezeptor antagonisten
US6331545B1 (en) *	1998-12-18	2001-12-18	Soo S. Ko	Heterocycyclic piperidines as modulators of chemokine receptor activity
US6387930B1 (en) *	1999-05-04	2002-05-14	Schering Corporation	Piperidine derivatives useful as CCR5 antagonists
US6294554B1 (en) *	1999-09-22	2001-09-25	Schering Corporation	Muscarinic antagonists
AR033517A1 (es) *	2000-04-08	2003-12-26	Astrazeneca Ab	Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0108876D0 (en) *	2001-04-09	2001-05-30	Novartis Ag	Organic Compounds
ATE319703T1 (de) *	2001-07-02	2006-03-15		Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
GB0117899D0 (en) *	2001-07-23	2001-09-12	Astrazeneca Ab	Chemical compounds
GB0120461D0 (en) *	2001-08-22	2001-10-17	Astrazeneca Ab	Novel compounds
GB0122503D0 (en) *	2001-09-18	2001-11-07	Astrazeneca Ab	Chemical compounds
SE0200844D0 (sv) *	2002-03-19	2002-03-19	Astrazeneca Ab	Chemical compounds
SE0200843D0 (sv) *	2002-03-19	2002-03-19	Astrazeneca Ab	Chemical compounds
SE0300850D0 (sv) *	2003-03-25	2003-03-25	Astrazeneca Ab	Chemical compounds
SE0300957D0 (sv) *	2003-04-01	2003-04-01	Astrazeneca Ab	Chemical compounds
SE0301368D0 (sv) *	2003-05-09	2003-05-09	Astrazeneca Ab	Chemical compounds

2002
- 2002-09-24 SE SE0202838A patent/SE0202838D0/xx unknown
2003
- 2003-09-12 MX MXPA05003007A patent/MXPA05003007A/es unknown
- 2003-09-12 AT AT03798620T patent/ATE368656T1/de not_active IP Right Cessation
- 2003-09-12 WO PCT/SE2003/001425 patent/WO2004029041A1/en not_active Ceased
- 2003-09-12 PL PL03376119A patent/PL376119A1/xx not_active Application Discontinuation
- 2003-09-12 DE DE60315323T patent/DE60315323T2/de not_active Expired - Fee Related
- 2003-09-12 KR KR1020057004938A patent/KR20050052511A/ko not_active Withdrawn
- 2003-09-12 RU RU2005105053/04A patent/RU2005105053A/ru not_active Application Discontinuation
- 2003-09-12 NZ NZ538527A patent/NZ538527A/en unknown
- 2003-09-12 CA CA002497280A patent/CA2497280A1/en not_active Abandoned
- 2003-09-12 BR BR0314688-0A patent/BR0314688A/pt not_active IP Right Cessation
- 2003-09-12 CN CNA038225026A patent/CN1684952A/zh active Pending
- 2003-09-12 EP EP03798620A patent/EP1546130B1/de not_active Expired - Lifetime
- 2003-09-12 EP EP07010143A patent/EP1816123A1/de not_active Withdrawn
- 2003-09-12 JP JP2004539695A patent/JP2006503066A/ja active Pending
- 2003-09-12 ES ES03798620T patent/ES2289354T3/es not_active Expired - Lifetime
- 2003-09-12 US US10/528,477 patent/US20060040984A1/en not_active Abandoned
- 2003-09-12 AU AU2003259004A patent/AU2003259004B2/en not_active Ceased
2005
- 2005-03-18 ZA ZA200502341A patent/ZA200502341B/en unknown
- 2005-04-20 IS IS7813A patent/IS7813A/is unknown
- 2005-04-22 NO NO20051965A patent/NO20051965L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
IS7813A (is)	2005-04-20
BR0314688A (pt)	2005-08-02
JP2006503066A (ja)	2006-01-26
DE60315323D1 (de)	2007-09-13
NZ538527A (en)	2006-10-27
EP1546130B1 (de)	2007-08-01
KR20050052511A (ko)	2005-06-02
EP1546130A1 (de)	2005-06-29
RU2005105053A (ru)	2005-12-10
ZA200502341B (en)	2005-09-19
EP1816123A1 (de)	2007-08-08
CA2497280A1 (en)	2004-04-08
US20060040984A1 (en)	2006-02-23
WO2004029041A1 (en)	2004-04-08
ES2289354T3 (es)	2008-02-01
SE0202838D0 (sv)	2002-09-24
PL376119A1 (en)	2005-12-12
MXPA05003007A (es)	2005-06-22
CN1684952A (zh)	2005-10-19
ATE368656T1 (de)	2007-08-15
AU2003259004B2 (en)	2007-02-08
DE60315323T2 (de)	2008-04-17
AU2003259004A1 (en)	2004-04-19
NO20051965D0 (no)	2005-04-22

Legal Events

Date	Code	Title	Description
2008-04-21	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20051965D0 (no)	2005-04-22	Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.
CY1106969T1 (el)	2012-09-26	Αναστολεις dpp-iv
NO20051036L (no)	2005-04-20	3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander
ATE275554T1 (de)	2004-09-15	Serinprotease-inhibitoren
TW200635918A (en)	2006-10-16	Pharmaceutical compounds
DE60131967D1 (de)	2008-01-31	Nr1h4-kern-rezeptor-bindende verbindungen
SE0301368D0 (sv)	2003-05-09	Chemical compounds
DE69915004D1 (de)	2004-04-01	5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
NO20051600L (no)	2005-06-13	1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
NO20080789L (no)	2008-02-13	1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
ZA200309887B (en)	2004-07-20	Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
NO20060324L (no)	2006-05-18	[1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
BRPI0409376A (pt)	2006-04-25	derivados de indeno como agentes farmacêuticos
DE60219643D1 (de)	2007-05-31	Heterozyklische carboxamide und ihre verwendung als fungizide
SE0200843D0 (sv)	2002-03-19	Chemical compounds
ATE453389T1 (de)	2010-01-15	Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
SE0300957D0 (sv)	2003-04-01	Chemical compounds
DE60329189D1 (de)	2009-10-22	Pyrrolidinderivate als oxytocin antagonisten
NO20060718L (no)	2006-03-01	Substituerte tiofoner og deres anvendelse
DE60227421D1 (de)	2008-08-14	Rmazeutische zusammensetzung und verwendung davon
ATE334977T1 (de)	2006-08-15	Discodermolid-analoga und ihre pharmazeutische verwendung
TH67425A (th)	2005-02-18	ไพราโซลีนคาร์บอกซานิลีดที่ถูกแทนที่
ATE404548T1 (de)	2008-08-15	Cyclisches hemiacetalderivat und dessen anwendung